Industry Webcast

Early Optimization of Basal Insulin in Type 2 Diabetes: Practical Strategies for Individualized Initiation and TitrationIndustry Webcast Sponsored by Sanofi; Not for CME/CE Credit

Type 2 Diabetes is a progressive disease that requires treatment modifications – yet fewer than 50% of individuals for whom insulin is considered to be needed actually receive it.* In a case-based educational podcast, Jennifer Goldman, PharmD, and Eugene Wright, MD explore the role of basal insulin in the individualized treatment of type 2 diabetes, emphasizing early optimization to reduce therapeutic inertia and help patients meet treatmvent goals in accordance with the 2026 ADA Standards of Care. (*Marrison ST, et al. Am Fam Physician. 2026;113(6):542-550). 

• Drs. Goldman and Wright led the virtual session on the Pri-Med platform. Sanofi Medical representative Jas Gill was also present at the session, and moderated the Q&A reactively by responding to audience questions that were asked in the virtual chat 
• Podcast cover photo not actual patient 
• This program is non-promotional medical education sponsored by Sanofi 
• No CME credits are available for this presentation 
• Presentation content was developed by Sanofi with input from the Speakers  
• The patient case study included in this presentation is hypothetical. Results may vary. Results from one case study are not necessarily predictive of results in other cases 
• This program is not to intended to substitute for independent clinical decision-making that is in the best interest of your patients 
• The Speakers were compensated and/or received an honorarium from Sanofi in connection with this presentation 
• Some information may not be consistent with the approved product labeling for the products(s) being discussed; this information may relate to the indication or use, dosage and administration, patient population, combination use, or other potential unapproved uses 
• No conclusions regarding safety and efficacy can be made for such uses